PRF Technologies (PRFX) Other Non-Current Liabilities (2020 - 2025)
PRF Technologies (PRFX) posted quarterly Other Non-Current Liabilities of $267000.0 for Q4 2025, up 3.09% year-on-year from $259000.0 in Q4 2024, and up 1.52% on a QoQ basis from $263000.0 in Q2 2025.
PRF Technologies (PRFX) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Other Non-Current Liabilities for 6 consecutive years, with $267000.0 the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 3.09% year-over-year to $267000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $267000.0 (up 3.09% YoY) and the FY2025 annual result came in at $267000.0, up 3.09% from the prior year.
- Other Non-Current Liabilities climbed to $267000.0 in Q4 2025 per PRFX's latest filing, from $263000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for PRFX reached as high as $267000.0 in Q4 2025 and fell as low as $220000.0 in Q2 2021.
- A 5-year average of $247700.0 and a median of $249000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities plunged 85.45% — and 2022, when it advanced 8.18%.
- Year by year, Other Non-Current Liabilities stood at $234000.0 in 2021, then increased by 3.85% to $243000.0 in 2022, then increased by 3.29% to $251000.0 in 2023, then advanced by 3.19% to $259000.0 in 2024, then grew by 3.09% to $267000.0 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $267000.0, $263000.0, and $259000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 267,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Dec 31, 2024 | 259,000.00 |
| Jun 30, 2024 | 255,000.00 |
| Dec 31, 2023 | 251,000.00 |
| Jun 30, 2023 | 247,000.00 |
| Dec 31, 2022 | 243,000.00 |
| Jun 30, 2022 | 238,000.00 |
| Dec 31, 2021 | 234,000.00 |
| Jun 30, 2021 | 220,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Sep 30, 2020 | 1.07 Mn |
| Jun 30, 2020 | 1.51 Mn |
| Mar 31, 2020 | 802,000.00 |